Phaseline

Companies › Teikoku Pharma USA

Teikoku Pharma USA: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dexmedetomidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2AgitationMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06052254DexmedetomidinePhase 2AgitationNeurologyMay 2027

Targets

ADRA2A (1) ADRA2C (1) ADRA2B (1)

Companies with the same targets

Guangzhou Novaken Pharm BioXcel Therapeutics Tarian Pharma Alcon Research Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas

Companies built like this

Guangzhou Novaken Pharm Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.